Los Angeles-Area A2 Biotherapeutics (www.a2bio.com) announced the closing of its $71.5M Series B financing round to fund the advancement of its Tmod (engineered T-cell module) platform that reportedly combines activating and blocking mechanisms to kill tumor cells and protect normal cells.
and related near-term product candidates.  Series B investors include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment. Here are links to related news stories.

https://www.businesswire.com/news/home/20201006005044/en/A2-Biotherapeutics-Closes-71.5M-Series-B-to-Begin-Clinical-Development-of-Its-Potentially-Transformative-Selective-Tumor-Cell-Therapeutics

https://www.prnewswire.com/news-releases/a2-biotherapeutics-closes-71-5m-series-b-to-begin-clinical-development-of-its-potentially-transformative-selective-tumor-cell-therapeutics-301145221.html